Skip to main content
. 2018 Feb 6;9(17):13593–13611. doi: 10.18632/oncotarget.24423

Figure 5. cAMP accumulation in recombinant CHO cell lines and in Jurkat-T cells.

Figure 5

(A) pEC50 values of AR agonists in cAMP accumulation assays in CHO-A2A, CHO-A2B and CHO-A2A-A2B cells. The one-way ANOVA with Dunnett’s post-hoc test indicated significant differences. ns: not significant, **p < 0.01, n = 2–4, see also Supplementary Table 4. The A2AAR agonist CGS-21680 showed only a negligible signal in CHO-A2A-A2B cells at concentrations of up to 100 µM. (B) pKB values for AR antagonists in cAMP accumulation assays in CHO-A2A, CHO-A2B and CHO-A2A-A2B cells with agonist stimulation by NECA. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences. ns: not significant, **p < 0.01, n = 4–6, see also Supplementary Table 4. (C) pEC50 values of agonists and pKB values of antagonists determined in cAMP accumulation assays at Jurkat-T cells (n = 3, see also Supplementary Table 4).